中文版Bioprogress
Who We Are
An executive search and talent acquisition specialist with a wealth of experience in the life science business sector
An alternative to the generalist search firms that offer only general search services
Able to find the right talent for you with the right approach and understanding the complexity of the life science industry
Able to build pools helping our clients to attract a long term and sustainable talent pipeline for current and future requirements, placing your company ahead of competition
Mr. Sam Meredith
Vice PresidentBIOS Health 
BIOS is unlocking the potential of the nervous system in treating chronic disease by using AI-powered neural interfaces that can automatically read and write neural signals. We have leveraged recent breakthroughs in AI and Machine Learning to translate the “language” of the nervous system for the first time. Being able to precisely link nerve activity to specific conditions through the discovery of their neural biomarkers is nothing short of a game-changer, holding the key to new treatments for conditions including heart disease and diabetes.
To find out more, contact us at partnerships@bios.health.
Mr. Emil Hewage
Co-Founder, CEOBiosion Inc., 
During the past several years, Biosion team has successfully built up multiple therapeutic antibody discovery pipelines for in-house development and for collaboration with our partners, thus enabling us to accelerate and broaden our innovative drug development capabilities for delivering novel drugs to patients in needs.
Dr. Mingjiu Chen
CEOBiostage, Inc. 
The company’s novel Cellframe™ technology is engineered to stimulate the body’s signaling pathways and natural healing process to regenerate and restore organ function. Our Cellframe technology is based on over 20 years of scientific progress in the fields of tissue engineering, cell biology and material science. Cellframe technology combines the best attributes of a synthetic scaffold with tissue engineering and cell biology to create what may be a revolutionary method of addressing organ damage.
Biostage has been developing its new generation of organ implants as a platform capable of being used in the esophagus and main airways (trachea and bronchi). The current platform, based on our Cellframe technology, represents a complete re-engineering of our earlier organ scaffold and cell technology to better stimulate the regenerative properties of each of these organs. Biostage’s Cellframe technology platform is used to create organ specific Cellspan implants. Recent large animal data showed promising results as our Cellframe technology applied to the esophagus achieved the regeneration of esophageal tissue.
Mr. Shunfu Hu
VP of Business Development and OperationsBiotrack Capital
嘉聪 郭
副总裁BioValleyCHINA Ventures
Assist Consultation, Assistance, Service
• Identify Distribution Opportunities, Partners, Joint Ventures
• Guidance for Product Registration (SFDA), Regulatory Issues
• Intellectual Property Assessment
• Develop Successful Business Strategy
• Marketing/Analysis
• Manufacturing/Sourcing
• Investment Advisory
Paul DeRidder
PresidentBioxytran/Pharmalectin
Academic study on a small number of patients with the first drug candidate had positive results. The viral load was reduced to zero in all mild/moderate patient after a few days. The drug is not toxic and had no adverse effects. It can prevent spread of infection in 24 hours. It is complementary to vaccination and can prevent infection from close contact. Next step is stage III trials for a bigger group of patients.
We are looking for investors to fund our next phase.
Responsive Web Design powered by 